Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial.
about
Inotropic agents and vasodilator strategies for acute myocardial infarction complicated by cardiogenic shock or low cardiac output syndromeInotropic agents and vasodilator strategies for acute myocardial infarction complicated by cardiogenic shock or low cardiac output syndromeGlioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2Cardiogenic Shock: Failure of Oxygen Delivery and Oxygen UtilizationPharmacology and Clinical Drug Candidates in Redox MedicineReactive Oxygen-Related Diseases: Therapeutic Targets and Emerging Clinical IndicationsUpregulation of xCT by KSHV-encoded microRNAs facilitates KSHV dissemination and persistence in an environment of oxidative stressCardiogenic shock due to myocardial infarction: diagnosis, monitoring and treatment: a German-Austrian S3 Guideline.Atherosclerosis: A Link Between Lipid Intake and Protein Tyrosine NitrationEarly revascularization is beneficial across all ages and a wide spectrum of cardiogenic shock severity: A pooled analysis of trials.Rapid complete reversal of systemic hypoperfusion after intra-aortic balloon pump counterpulsation and survival in cardiogenic shock complicating an acute myocardial infarctionInhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.Addressing the challenges of a cross-national investigation: lessons from the Pittsburgh-Pisa study of treatment-relevant phenotypes of unipolar depression.Intra-aortic balloon pump may grant no benefit to improve the mortality of patients with acute myocardial infarction in short and long term: an updated meta-analysisEfficacy and timing of intra-aortic counterpulsation in patients with ST-elevation myocardial infarction complicated by cardiogenic shock.Percutaneous assist devices in acute myocardial infarction with cardiogenic shock: Review, meta-analysisEffect of early statin treatment in patients with cardiogenic shock complicating acute myocardial infarctionPercutaneous mechanical cardiac assist in myocardial infarction. Where are we now, where are we going?Interleukin-1β, lipocalin 2 and nitric oxide synthase 2 are mechano-responsive mediators of mouse and human endothelial cell-osteoblast crosstalk.Pharmacological optimization of tissue perfusion.The Use of Intra-aortic Balloon Pump in a Real-World Setting: A Comparison between Survivors and Nonsurvivors from Acute Coronary Syndrome Treated with IABP. The Jakarta Acute Coronary Syndrome Registry.A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines?Bench-to-bedside review: nitric oxide in critical illness--update 2008.Nitric oxide synthase inhibitors in cardiogenic shock: present and future.Nitric oxide and redox regulation in the liver: part II. Redox biology in pathologic hepatocytes and implications for intervention.Reactive nitroxidative species and nociceptive processing: determining the roles for nitric oxide, superoxide, and peroxynitrite in pain.Shock in acute myocardial infarction: the Cape Horn for trials?Cardiogenic shock: the role of inflammation.Pathophysiology, diagnosis, and treatment of infarction-related cardiogenic shock.Post myocardial infarction cardiogenic shock: a review of current therapies.Cardiogenic shock in ACS. Part 1: prediction, presentation and medical therapy.Translating metabolomics to cardiovascular biomarkers.Therapeutic strategies for high-dose vasopressor-dependent shock.Pharmacologic therapy for reducing myocardial infarct size in clinical trials: failed and promising approaches.Management of cardiogenic shock.Methylene blue treatment for cytokine release syndrome-associated vasoplegia following a renal transplant with rATG infusion: A case report and literature review.Nitric oxide inhibition strategies.Outcome of elderly undergoing extracorporeal life support in refractory cardiogenic shock.[Modern drug therapy in cardiovascular intensive care medicine].Soluble ST2 levels in patients with cardiogenic and septic shock are not predictors of mortality.
P2860
Q24201225-6117463D-4EDB-460E-82E7-502FBA35358BQ24203783-352A384D-BCED-400D-9BEE-C3419F229B4DQ24628857-570641AE-A9F8-4936-9D73-DF27DF8601D4Q26742020-D1B8E024-7FE0-49E7-8D26-6496E7796B85Q26785525-ABB81BD6-275F-4C8D-8AEB-A627C88A34FCQ27024762-F4921AFA-F405-4FB1-8260-F33E99B0CF9FQ28472699-C0A51C74-A10A-4B6B-BEFA-D684887D3386Q30318082-1660C629-4AE4-4532-B1CD-AE8E9EC34876Q33649712-A2348F84-5A60-471C-AB61-89D368EAB539Q34471018-995A94C4-E185-4AC7-AE4C-685D33B4C569Q35163124-01E935BC-765D-4758-9808-8C378883BE60Q35258324-8B9375B6-D041-450F-A337-FC716D312A6CQ36070590-684CB385-FD13-40C8-BE51-E1224141DF21Q36151537-FED5D10A-7851-4259-B3F4-B31CAD39037AQ36227295-C04742D6-3912-4D09-A3FC-037C5211A9DEQ36505924-114CBACC-5D9D-4AA5-8B51-E4D7BD41F88BQ36681810-4DB93F55-D589-42E8-9AEA-3CD62A62B5A6Q36966769-8AFA05CF-7F17-4B5D-9CB1-87A130D1E96EQ37105025-6762F68F-46BC-476C-B3AD-4FC19445B691Q37236713-D34FCA69-D48F-4F28-9701-B003CAD817F9Q37315377-395972A1-5464-4727-B7B1-BFEDB779C683Q37377110-2CE8CBE3-F2F8-4E4D-AA97-773FB53B89CBQ37576051-C9FBCE9C-8672-40A8-BCB1-54F3D322B813Q37608590-0DB267B8-090F-4529-AC1D-A9A8188ACAEBQ37733072-31BD8D08-43D5-4856-8D91-D551CE49CAD5Q37765512-42058C73-53F3-411C-991B-52C24B80AE89Q37770822-E29EA7EC-3C63-48C9-96BC-DD1C4738BC5CQ37805473-77F82893-C7F0-4877-92D3-FA72B0A2F151Q37855618-9E1D78BA-D1B4-42E1-9975-9DE13C991F22Q37900083-B6FB4798-345F-41B8-91D9-F78C66E1602BQ37969891-E42FCEFA-D964-4FD4-882B-0E24A62A79ADQ38028672-92655E77-FE23-4D3C-8A62-E0682B8A5F50Q38154892-E1B164A0-24C5-40F2-AAEF-3944BE199CE6Q38225491-304FF15E-0408-4144-AC2E-3A43EEE095DDQ38366956-257EF208-9E23-42EF-87DE-4411D66F9DDEQ38542070-B99AE26A-CA8C-4426-BDD8-BD1CC84550E2Q38935631-33EEED81-C6A1-4D09-B1F7-304CBF20EE2DQ39017618-2448FF14-C4D4-4303-9915-097A65BE152FQ39188101-0F3C38CD-0D79-4BB8-8846-C8913DF301B9Q39868169-CB041146-A367-4790-81E9-003DB657CE33
P2860
Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Effect of tilarginine acetate ...... H randomized controlled trial.
@en
type
label
Effect of tilarginine acetate ...... H randomized controlled trial.
@en
prefLabel
Effect of tilarginine acetate ...... H randomized controlled trial.
@en
P2093
P50
P1476
Effect of tilarginine acetate ...... H randomized controlled trial.
@en
P2093
John H Alexander
TRIUMPH Investigators
Vladimir Dzavik
P304
P356
10.1001/JAMA.297.15.JOC70035
P407
P577
2007-03-26T00:00:00Z